Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci

被引：26

作者：

Fasola, E

Spangler, SK

Ednie, LM

Jacobs, MR

Bajaksouzian, S

Appelbaum, PC

机构：

[1] PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT PATHOL, HERSHEY, PA 17033 USA

[2] CASE WESTERN RESERVE UNIV, DEPT PATHOL CLIN MICROBIOL, CLEVELAND, OH 44106 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1996年 / 40卷 / 11期

关键词：

D O I：

10.1128/AAC.40.11.2661

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Microdilution MIC testing was used to test the susceptibility of 202 pneumococci to LY 333328 and six other agents. LY 333328 was the most active glycopeptide (MIG at which 90% of the pneumococci were inhibited [MIC(90)], 0.008 mu g/ml), followed by teicoplanin (MIC(90), 0.06 mu g/ml) and vancomycin (MIC(90), 0.5 mu g/ml). Rifampin resistance was seen in some penicillin-resistant strains. The MICs of imipenem and ceftriaxone rose with those of penicillin. Time-kill testing confirmed the excellent antipneumococcal activity of LY 333328.

引用

页码：2661 / 2663

页数：3

共 18 条

[1] ANTIMICROBIAL RESISTANCE IN STREPTOCOCCUS-PNEUMONIAE - AN OVERVIEW [J].

APPELBAUM, PC .

CLINICAL INFECTIOUS DISEASES, 1992, 15 (01) :77-83

[2]

BLOCK S, 1994, MMWR-MORBID MORTAL W, V43, P31

[3]

BOYLAN CJ, 1995, 35 INT C ANT AG CHEM, P157

[4] EMERGENCE OF DRUG-RESISTANT PNEUMOCOCCAL INFECTIONS IN THE UNITED-STATES [J].

BREIMAN, RF ;

BUTLER, JC ;

TENOVER, FC ;

ELLIOTT, JA ;

FACKLAM, RR .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (23) :1831-1835

[5]

Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P23

[6]

FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607

[7] COMPARATIVE ACTIVITY OF TEICOPLANIN AND VANCOMYCIN AGAINST 400 PENICILLIN-SUSCEPTIBLE AND RESISTANT STREPTOCOCCUS-PNEUMONIAE [J].

GOLDSTEIN, FW ;

GESLIN, P ;

ACAR, JE ;

AKLI, J ;

ALLOUCH, P ;

BEBEAR, C ;

BLONDEL, P ;

BOISIVON, A ;

BURDIN, JC ;

CHARDON, H ;

COUPRY, A ;

CROIX, JC ;

DORCHE, G ;

FIEVET, P ;

GEFFROY, F ;

GRILLOT, ML ;

HAUTEFORT, B ;

LARROUY, M ;

LEFRAND, H ;

LEMELAND, JF ;

LIBERT, JM ;

MARMONIER, A ;

MELON, M ;

NICOLAS, MH ;

REVEIL, JC ;

RIO, Y ;

SANCHEZ, R ;

SEDAILLAN, A .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1994, 13 (01) :33-34

[8] TREATMENT AND DIAGNOSIS OF INFECTIONS CAUSED BY DRUG-RESISTANT STREPTOCOCCUS-PNEUMONIAE [J].

JACOBS, MR .

CLINICAL INFECTIOUS DISEASES, 1992, 15 (01) :119-127

[9] Relationship of MICs to efficacy of cefotaxime in treatment of Streptococcus pneumoniae infections [J].

Jacobs, RF ;

Kaplan, SL ;

Schutze, GE ;

Dajani, AS ;

Leggiadro, RJ ;

Rim, CS ;

Puri, SK .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (04) :895-898

[10] RANDOMIZED COMPARISON OF MEROPENEM WITH CEFOTAXIME FOR TREATMENT OF BACTERIAL-MENINGITIS [J].

KLUGMAN, KP ;

DAGAN, R ;

WILLIAMS, KJ ;

FEATHERSTONE, A ;

BEATTY, D ;

LEARY, M ;

WALKER, K ;

RODDA, J ;

SCHER, G ;

HOUSEHAM, C ;

PELSAR, H ;

LOPEZ, E ;

FALLO, L ;

TREGNAGHI, MW ;

AIRD, A ;

DEAPRA, EQ ;

BEGUE, P ;

BOULESTEIX, J ;

FLORET, D ;

ASTRUC, J ;

BOUILLE, C ;

CARRIERE, JP .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (05) :1140-1146

← 1 2 →